Amgen (4332) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4332 Analyst Ratings

Moderate Buy

14 Buy

10 Hold

1 Sell

Based on 25 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4332 Stock 12 Month Forecast

Average Price Target

HK$2,896.38

―

Based on 25 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is HK$2,896.38 with a high forecast of HK$3,377.61 and a low forecast of HK$2,306.47. The average price target represents a 1609000.44% change from the last price of HK$0.18.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3378":"HK$3,378","-1":"-HK$1","843.75":"HK$843.8","1688.5":"HK$1,688.5","2533.25":"HK$2,533.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3377.61237312,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$3.38K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2896.3807954219997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$2.90K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2306.4714122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$2.31K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,843.75,1688.5,2533.25,3378],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.185,259.98710562461537,519.7892112492307,779.591316873846,1039.3934224984614,1299.1955281230767,1558.9976337476921,1818.7997393723076,2078.601844996923,2338.403950621538,2598.2060562461534,2858.008161870769,3117.8102674953843,{"y":3377.61237312,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.185,222.96929195553844,445.7535839110769,668.5378758666152,891.3221678221537,1114.1064597776922,1336.8907517332304,1559.675043688769,1782.4593356443074,2005.243627599846,2228.0279195553844,2450.8122115109227,2673.596503466461,{"y":2896.3807954219997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.185,177.5916470923077,354.9982941846154,532.4049412769231,709.8115883692308,887.2182354615385,1064.6248825538462,1242.031529646154,1419.4381767384616,1596.8448238307692,1774.251470923077,1951.6581180153848,2129.0647651076924,{"y":2306.4714122,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1686.776,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1686.776,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1686.776,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1704.781,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1704.781,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1704.781,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1722.976,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1722.976,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1722.976,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1741.299,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1741.299,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1741.299,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.185,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$3,378

Average Price TargetHK$2,896

Lowest Price TargetHK$2,306

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Amsellem

Piper Sandler

HK$3,377.61

Buy

1876351.32%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Radnet (NASDAQ: RDNT), Amgen (NASDAQ: AMGN) and Eli Lilly & Co (NYSE: LLY)

Gregory Renza

Truist Financial

―

Hold

―

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), ANI Pharmaceuticals (NASDAQ: ANIP) and ALX Oncology Holdings (NASDAQ: ALXO)

Mohit Bansal

Wells Fargo

HK$2,541.03→HK$2,931.96

Hold

1628763.99%

Upside

Reiterated

02/19/26

Amgen price target raised to $375 from $325 at Wells FargoAmgen price target raised to $375 from $325 at Wells Fargo

Emily Field

Barclays

HK$2,736.49

Hold

1520173.06%

Upside

Initiated

02/19/26

Amgen initiated with an Equal Weight at BarclaysAmgen initiated with an Equal Weight at Barclays

Salim Syed

Mizuho Securities

HK$2,189.19→HK$2,306.47

Hold

1281273.01%

Upside

Reiterated

02/11/26

Amgen price target raised to $295 from $280 at MizuhoAmgen price target raised to $295 from $280 at Mizuho

Unknown Analyst

Argus Research

Not Ranked

Argus Research

HK$3,127.42

Buy

1737354.92%

Upside

Reiterated

02/06/26

Amgen (AMGN) Receives a Buy from Argus Research

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

HK$2,384.66→HK$2,713.04

Hold

1507142.15%

Upside

Reiterated

02/05/26

Guggenheim Remains a Hold on Amgen (AMGN)

Geoff Meacham

Citi

HK$2,462.84→HK$2,697.4

Hold

1498454.87%

Upside

Reiterated

02/04/26

Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating

Terence Flynn

Morgan Stanley

HK$2,376.84→HK$2,415.93

Hold

1342083.93%

Upside

Reiterated

02/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Caribou Biosciences (NASDAQ: CRBU) and Boston Scientific (NYSE: BSX)

Evan Seigerman

BMO Capital

HK$2,908.5

Buy

1615733.08%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck & Company (NYSE: MRK)

Salveen Richter

Goldman Sachs

HK$3,244.7

Buy

1802509.48%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Johnson & Johnson (NYSE: JNJ)

Carter Gould

Cantor Fitzgerald

HK$2,462.84→HK$2,736.49

Hold

1520173.06%

Upside

Reiterated

02/04/26

Cantor Fitzgerald Sticks to Its Hold Rating for Amgen (AMGN)

Louise Chen

Scotiabank

HK$3,010.14

Buy

1672200.36%

Upside

Reiterated

02/04/26

Scotiabank Keeps Their Buy Rating on Amgen (AMGN)

Matt Phipps

William Blair

―

Buy

―

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and BeOne Medicines (NASDAQ: ONC)

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

02/04/26

Evercore ISI Remains a Buy on Amgen (AMGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Amsellem

Piper Sandler

HK$3,377.61

Buy

1876351.32%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Radnet (NASDAQ: RDNT), Amgen (NASDAQ: AMGN) and Eli Lilly & Co (NYSE: LLY)

Gregory Renza

Truist Financial

―

Hold

―

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), ANI Pharmaceuticals (NASDAQ: ANIP) and ALX Oncology Holdings (NASDAQ: ALXO)

Mohit Bansal

Wells Fargo

HK$2,541.03→HK$2,931.96

Hold

1628763.99%

Upside

Reiterated

02/19/26

Amgen price target raised to $375 from $325 at Wells FargoAmgen price target raised to $375 from $325 at Wells Fargo

Emily Field

Barclays

HK$2,736.49

Hold

1520173.06%

Upside

Initiated

02/19/26

Amgen initiated with an Equal Weight at BarclaysAmgen initiated with an Equal Weight at Barclays

Salim Syed

Mizuho Securities

HK$2,189.19→HK$2,306.47

Hold

1281273.01%

Upside

Reiterated

02/11/26

Amgen price target raised to $295 from $280 at MizuhoAmgen price target raised to $295 from $280 at Mizuho

Unknown Analyst

Argus Research

Not Ranked

Argus Research

HK$3,127.42

Buy

1737354.92%

Upside

Reiterated

02/06/26

Amgen (AMGN) Receives a Buy from Argus Research

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

HK$2,384.66→HK$2,713.04

Hold

1507142.15%

Upside

Reiterated

02/05/26

Guggenheim Remains a Hold on Amgen (AMGN)

Geoff Meacham

Citi

HK$2,462.84→HK$2,697.4

Hold

1498454.87%

Upside

Reiterated

02/04/26

Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating

Terence Flynn

Morgan Stanley

HK$2,376.84→HK$2,415.93

Hold

1342083.93%

Upside

Reiterated

02/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Caribou Biosciences (NASDAQ: CRBU) and Boston Scientific (NYSE: BSX)

Evan Seigerman

BMO Capital

HK$2,908.5

Buy

1615733.08%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck & Company (NYSE: MRK)

Salveen Richter

Goldman Sachs

HK$3,244.7

Buy

1802509.48%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Johnson & Johnson (NYSE: JNJ)

Carter Gould

Cantor Fitzgerald

HK$2,462.84→HK$2,736.49

Hold

1520173.06%

Upside

Reiterated

02/04/26

Cantor Fitzgerald Sticks to Its Hold Rating for Amgen (AMGN)

Louise Chen

Scotiabank

HK$3,010.14

Buy

1672200.36%

Upside

Reiterated

02/04/26

Scotiabank Keeps Their Buy Rating on Amgen (AMGN)

Matt Phipps

William Blair

―

Buy

―

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and BeOne Medicines (NASDAQ: ONC)

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

02/04/26

Evercore ISI Remains a Buy on Amgen (AMGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months

xxx

Success Rate

11/14 ratings generated profit

Average Return

+8.71%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +8.71% per trade.

1 Year

David AmsellemPiper Sandler

Success Rate

14/14 ratings generated profit

Average Return

+28.99%

a rating ―

Copying David Amsellem's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +28.99% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+32.45%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +32.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4332 Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4332 has received 24 Buy Ratings, 16 Hold Ratings, and 2 Sell Ratings. 4332 average Analyst price target in the past 3 months is 2,896.38.

Each month's total comprises the sum of three months' worth of ratings.

4332 Financial Forecast

4332 Earnings Forecast

Next quarter’s earnings estimate for 4332 is HK$37.64 with a range of HK$32.60 to HK$48.08. The previous quarter’s EPS was HK$41.36. 4332 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 4332 has Performed in-line its overall industry.

4332 Sales Forecast

Next quarter’s sales forecast for 4332 is HK$67.43B with a range of HK$65.07B to HK$72.40B. The previous quarter’s sales results were HK$77.37B. 4332 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 4332 has Performed in-line its overall industry.

4332 Stock Forecast FAQ

What is HK:4332’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 2,896.38.

What is HK:4332’s upside potential, based on the analysts’ average price target?

Amgen has 1609000.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Amgen a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy, which is based on 14 buy ratings, 10 hold ratings and 1 sell ratings.

What is Amgen’s share price target?

The average share price target for Amgen is 2,896.38. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$3,377.61 ,and the lowest forecast is HK$2,306.47. The average share price target represents 1609000.44% Increase from the current price of HK$0.18.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Streets Analysts.

How can I buy shares of Amgen?

To buy shares of HK:4332, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Amgen (4332) Stock Forecast & Price Target

4332 Analyst Ratings

4332 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

4332 Analyst Recommendation Trends

4332 Financial Forecast

4332 Earnings Forecast

4332 Sales Forecast

4332 Stock Forecast FAQ

Detailed List of Analyst Forecasts